Literature DB >> 15787829

A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: treatment with a combination of amphotericin B and 5-flucytosine.

S-G Park1, S-H Oh, S-B Suh, K-H Lee, K-Y Chung.   

Abstract

Chromoblastomycosis is a cutaneous and subcutaneous mycotic disease caused by the dematiaceous (black) fungi. Five species of fungi are known generally to be the cause: Fonsecaea pedrosoi, Phialophora verrucosa, Cladosporium carrionii, F. compacta and Rhinocladiella cerphilum. In infected tissue they can appear as pigmented sclerotic bodies, commonly called 'copper pennies', which are pathognomonic of chromoblastomycosis. The infection usually occurs through traumatic skin inoculation, with the majority of lesions occurring on the feet and legs of outdoor workers. We report a patient in whom the lesions had begun on the right breast, which is an unexposed area, without a history of trauma. A uniform, reliable treatment does not exist but our patient was mycologically cured with the use of amphotericin B and the subsequent combination of 5-flucytosine and itraconazole.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15787829     DOI: 10.1111/j.1365-2133.2005.06424.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

1.  Attritional extensor tendon rupture in a patient with Phialophora verrucosa tenosynovitis: case report.

Authors:  Michael Sorkin; Theodore A Kung; Kevin C Chung
Journal:  Hand (N Y)       Date:  2015-06

2.  In vitro activities of nine antifungal drugs and their combinations against Phialophora verrucosa.

Authors:  Yali Li; Zhe Wan; Ruoyu Li
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

3.  Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.

Authors:  S Deng; W Lei; G S de Hoog; L Yang; R G Vitale; H Rafati; M Seyedmousavi; A Tolooe; H van der Lee; W Liao; P E Verweij; S Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

4.  A Clinico-Mycological Study on Suspected Cases of Chromoblastomycosis: Challenges in Diagnosis and Management.

Authors:  Hirak Jyoti Raj; Banashree Majumdar; Atul Jain; Prasanta Kumar Maiti; Gobinda Chatterjee
Journal:  J Clin Diagn Res       Date:  2015-12-01

5.  Chromoblastomycosis Caused by Fonsecaea pedrosoi.

Authors:  Dong Min Kim; Sung Min Hwang; Moo Kyu Suh; Gyoung Yim Ha; Gwang Seong Choi; Jeonghyun Shin; Sung Hyub Han
Journal:  Ann Dermatol       Date:  2011-08-06       Impact factor: 1.444

6.  Oral chromoblastomycosis: a case report.

Authors:  M J Fatemi; Fatemi Mj; H Bateni; Bateni H
Journal:  Iran J Microbiol       Date:  2012-03

Review 7.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

8.  Amphotericin-B in Dermatology.

Authors:  Akash Agarwal; Bikash R Kar
Journal:  Indian Dermatol Online J       Date:  2022-01-24

9.  New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole.

Authors:  Rowena Alves Coelho; Gabriela Machado Alves; Maria Helena Galdino Figueiredo-Carvalho; Fernando Almeida-Silva; Gabriela Rodrigues de Souza; Maria Cristina da Silva Lourenço; Fábio Brito-Santos; Ana Claudia Fernandes Amaral; Rodrigo Almeida-Paes
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-09-12       Impact factor: 2.747

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.